Initiator Pharma (INIT.ST) Stock Analysis & AI Equity Report
Initiator Pharma (INIT.ST) overview
Initiator Pharma (INIT.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Initiator Pharma reported revenue of DKK 0m and operating profit of DKK -18.2m; the year-end share price was 2.96 SEK and market capitalisation was SEK 184m. Initiator Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Initiator Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Initiator Pharma
Initiator Pharma A/S is a Danish clinical-stage biotechnology company developing drug candidates that target the central and peripheral nervous system. Its lead program, pudafensine, is being advanced for erectile dysfunction and vulvodynia, with additional preclinical assets in the pipeline. The company has also said it is focusing resources on pudafensine as its main strategic priority.
Generate the Initiator Pharma report
Initiator Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Initiator Pharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Initiator Pharma
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.